tradingkey.logo

Biofrontera Inc

BFRI
0.766USD
+0.006+0.72%
收盤 12/19, 16:00美東報價延遲15分鐘
8.92M總市值
虧損本益比TTM

Biofrontera Inc

0.766
+0.006+0.72%

關於 Biofrontera Inc 公司

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

Biofrontera Inc簡介

公司代碼BFRI
公司名稱Biofrontera Inc
上市日期Oct 14, 2021
CEOLuebbert (Hermann)
員工數量92
證券類型Ordinary Share
年結日Oct 14
公司地址120 Presidential Way,
城市WOBURN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編01801
電話17812451325
網址https://www.biofrontera-us.com/
公司代碼BFRI
上市日期Oct 14, 2021
CEOLuebbert (Hermann)

Biofrontera Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Mr. George Jones
Mr. George Jones
Chief Commercial Officer
Chief Commercial Officer
--
--
名稱
名稱/職務
職務
持股
持股變動
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
152.71K
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
87.50K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--

收入明細

FY2024
FY2023
FY2022
FY2021
由於公司未披露,未能獲取相關數據
地區USD
名稱
營收
佔比
United States
37.32M
0.00%
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.79%
AIGH Capital Management, LLC.
7.86%
Hewlett Fund, L.P.
4.05%
Biofrontera AG
3.43%
Lytton (Laurence W)
2.63%
其他
72.23%
持股股東
持股股東
佔比
Rosalind Advisors, Inc.
9.79%
AIGH Capital Management, LLC.
7.86%
Hewlett Fund, L.P.
4.05%
Biofrontera AG
3.43%
Lytton (Laurence W)
2.63%
其他
72.23%
股東類型
持股股東
佔比
Hedge Fund
12.69%
Private Equity
8.36%
Corporation
7.49%
Individual Investor
4.70%
Investment Advisor/Hedge Fund
2.49%
Investment Advisor
1.67%
Venture Capital
0.15%
Research Firm
0.05%
其他
62.39%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
34
2.85M
28.39%
--
2025Q3
35
2.85M
24.13%
+509.58K
2025Q2
38
2.48M
28.99%
+6.08K
2025Q1
43
1.91M
35.97%
-1.28M
2024Q4
42
2.24M
20.22%
+365.98K
2024Q3
37
1.95M
35.26%
+44.70K
2024Q2
40
1.95M
40.02%
-47.81K
2024Q1
39
1.85M
15.80%
+1.04M
2023Q4
36
279.45K
16.52%
+54.33K
2023Q3
39
75.19K
10.29%
-23.48K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Rosalind Advisors, Inc.
644.39K
6.04%
--
--
Aug 13, 2025
AIGH Capital Management, LLC.
914.21K
8.57%
--
--
Aug 13, 2025
Hewlett Fund, L.P.
550.22K
5.16%
--
--
Aug 13, 2025
Biofrontera AG
400.00K
3.75%
--
--
Sep 16, 2025
Lytton (Laurence W)
306.70K
2.87%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
2.73%
+141.15K
+94.10%
Sep 30, 2024
Worth Venture Partners, LLC
249.36K
2.34%
-125.08K
-33.41%
Jun 30, 2025
Luebbert (Hermann)
152.71K
1.43%
+137.50K
+903.95%
Sep 10, 2025
The Vanguard Group, Inc.
14.92K
0.14%
--
--
Aug 31, 2025
Leffler (Eugene Frederick)
87.50K
0.82%
+87.50K
--
Sep 10, 2025
查看更多

持股ETF

機構名稱
佔比
暫無數據

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
公告日期
類型
比率
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1
Jul 03, 2023
Merger
20→1

常見問題

Biofrontera Inc的前五大股東是誰?

Biofrontera Inc的前五大股東如下:
Rosalind Advisors, Inc.
持有股份:644.39K
佔總股份比例:6.04%。
AIGH Capital Management, LLC.
持有股份:914.21K
佔總股份比例:8.57%。
Hewlett Fund, L.P.
持有股份:550.22K
佔總股份比例:5.16%。
Biofrontera AG
持有股份:400.00K
佔總股份比例:3.75%。
Lytton (Laurence W)
持有股份:306.70K
佔總股份比例:2.87%。

Biofrontera Inc的前三大股東類型是什麼?

Biofrontera Inc 的前三大股東類型分別是:
Rosalind Advisors, Inc.
AIGH Capital Management, LLC.
Hewlett Fund, L.P.

有多少機構持有Biofrontera Inc(BFRI)的股份?

截至2025Q4,共有34家機構持有Biofrontera Inc的股份,合計持有的股份價值約為2.85M,占公司總股份的28.39% 。與2025Q3相比,機構持股有所增加,增幅為4.26%。

哪個業務部門對Biofrontera Inc的收入貢獻最大?

在FY2024,--業務部門對Biofrontera Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI